Schizophrenia |
Schizoid personality disorder; Schizotypal personality disorder |
Clinical Trial: One Year Drug Treatment in First-Episode Schizophrenia
This study is no longer recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Schizophrenia | Drug: Haloperidol, Risperidone (drug) | Phase IV |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: One Year Maintenance Treatment with Low Dose Haloperidol Vs. Risperidone in First-Episode Schizophrenia
Secondary Outcomes: 1 year course regarding psychopathology; social and cognitive functioning; side-effects; drop-out; quality of life
Expected Total Enrollment: 159
Study start: November 2000; Study completion: December 2005
Last follow-up: April 2005; Data entry closure: September 2005
Eligibility
Inclusion Criteria:
- First-episode in schizophrenia (according ICD-10 F20)
- Age between 18 and 55
- Informed consent
Exclusion Criteria:
- Residence outside of the catchment area
- Legal reasons
- Insufficient knowledge of the german language
- Substance abuse or addiction
- Pregnancy
- Serious physical illness
- Organic brain disease
- Contraindication to neuroleptic treatment
Location Information
Germany, North Rhine-Westphalia
Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University, Duesseldorf, North Rhine-Westphalia, 40629, Germany
Wolfgang Gaebel, Professor, Study Chair, Department of Psychiatry and Psychotherapy, University of Duesseldorf
More Information
Publications
Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, Von Wilmsdorff M, Bottlender R, Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):129-40.
Last Updated: September 11, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00159081
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2005-09-13

Not Signed In -


